Enovis Corp (ENOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enovis Corp (ENOV) has a cash flow conversion efficiency ratio of 0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($75.03 Million) by net assets ($1.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Enovis Corp for the company's overall valuation and market capitalisation.
Enovis Corp - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Enovis Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Enovis Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enovis Corp ranked by their cash flow conversion efficiency. Explore ENOV cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
0.047x |
|
Hengkang Medical Group Co Ltd
SHE:002219
|
0.005x |
|
ZEAL Network SE
XETRA:TIMA
|
0.163x |
|
Shanghai STEP Electric Corp
SHE:002527
|
0.009x |
|
Altareit
PA:AREIT
|
0.051x |
|
Helix Energy Solutions Group Inc
NYSE:HLX
|
0.015x |
|
Amoy Diagnostics Co Ltd
SHE:300685
|
0.059x |
|
TotalEnergies EP Gabon S.A.
PA:EC
|
0.068x |
Annual Cash Flow Conversion Efficiency for Enovis Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Enovis Corp from 2005 to 2025. View ENOV stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.49 Billion | $217.29 Million | 0.146x | +229.05% |
| 2024-12-31 | $2.56 Billion | $113.50 Million | 0.044x | +12.17% |
| 2023-12-31 | $3.42 Billion | $134.99 Million | 0.039x | +343.71% |
| 2022-12-31 | $3.45 Billion | $-55.86 Million | -0.016x | -121.20% |
| 2021-12-31 | $4.66 Billion | $356.10 Million | 0.076x | -9.22% |
| 2020-12-31 | $3.59 Billion | $301.94 Million | 0.084x | +124.26% |
| 2019-12-31 | $3.49 Billion | $130.95 Million | 0.038x | -42.36% |
| 2018-12-31 | $3.48 Billion | $226.37 Million | 0.065x | +10.92% |
| 2017-12-31 | $3.73 Billion | $218.77 Million | 0.059x | -26.49% |
| 2016-12-31 | $3.09 Billion | $246.97 Million | 0.080x | -14.42% |
| 2015-12-31 | $3.26 Billion | $303.81 Million | 0.093x | -18.92% |
| 2014-12-31 | $3.35 Billion | $385.76 Million | 0.115x | -12.91% |
| 2013-12-31 | $2.74 Billion | $362.17 Million | 0.132x | +73.40% |
| 2012-12-31 | $2.16 Billion | $164.30 Million | 0.076x | -74.77% |
| 2011-12-31 | $189.28 Million | $57.15 Million | 0.302x | +5.44% |
| 2010-12-31 | $216.37 Million | $61.97 Million | 0.286x | +48.73% |
| 2009-12-31 | $198.83 Million | $38.29 Million | 0.193x | +202.00% |
| 2008-12-31 | $166.93 Million | $-31.51 Million | -0.189x | -113.45% |
| 2007-12-31 | $53.05 Million | $74.48 Million | 1.404x | +147.72% |
| 2006-12-31 | $5.90 Million | $-17.36 Million | -2.942x | -387.56% |
| 2005-12-31 | $-7.58 Million | $-7.75 Million | 1.023x | -- |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more